简讯：RNA药物研发龙头企业瑞博生物通过港交所聆讯

Core Viewpoint - Suzhou Ribo Bioengineering Co., Ltd., a leader in RNA drug development, has passed the Hong Kong Stock Exchange listing hearing, marking a new phase in its IPO process [2] Company Summary - In the first half of this year, Ribo Bio reported a revenue growth of 56.6%, reaching 103.8 million yuan (approximately 14.7 million USD), compared to 66.3 million yuan in the same period last year [2] - The company's losses narrowed to 97.8 million yuan, an improvement from 141.6 million yuan in the previous year [2] - Established in 2007, Ribo Bio specializes in RNA small nucleic acid drug development, focusing on therapies that utilize small interfering RNA (siRNA) to block pathogenic gene activity [2] - The company claims to have one of the richest siRNA development pipelines globally, with seven clinical-stage candidate drugs targeting cardiovascular, metabolic, renal, and liver diseases, four of which have entered Phase II clinical trials [2] - Ribo Bio has entered into licensing agreements with several industry peers, including Qilu Pharmaceutical, which obtained the rights to produce and sell its cholesterol-lowering drug in mainland China and Hong Kong and Macau [2] - In 2023, the company signed a collaboration agreement with Boehringer Ingelheim, valued at over 2 billion USD, to jointly advance small nucleic acid drug development [2] Industry Summary - Research cited in the prospectus indicates that the global small nucleic acid drug market is expected to reach 54.9 billion USD by 2034, with a compound annual growth rate (CAGR) of 29.4% from 2024 to 2029 [3] - By 2024, siRNA drugs are projected to account for approximately 44.5% of this market [3]